AI assistant
Evaxion A/S — Capital/Financing Update 2024
Jan 22, 2024
34884_ffr_2024-01-22_e2320f24-ae1d-4881-9680-e1bd4b328b2e.zip
Capital/Financing Update
Open in viewerOpens in your device viewer
6-K 1 tm243814d1_6k.htm FORM 6-K
Field: Rule-Page
Field: /Rule-Page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Field: Rule-Page
Field: /Rule-Page
FORM 6-K
Field: Rule-Page
Field: /Rule-Page
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2024
Commission File Number: 001-39950
Field: Rule-Page
Field: /Rule-Page
Evaxion Biotech A/S
(Exact Name of Registrant as Specified in Its Charter)
Field: Rule-Page
Field: /Rule-Page
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Field: Rule-Page
Field: /Rule-Page
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Field: Rule-Page
Field: /Rule-Page
Field: Page; Sequence: 1
Field: /Page
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132) and on Form F-1, as amended (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Field: Page; Sequence: 2
Field: /Page
Press Release
On January 22, 2024, Evaxion Biotech A/S (the “Company”) issued a press release announcing the Company’s previously disclosed change to its American Depositary Share (“ADS”) to ordinary share ratio has been made effective on January 22, 2024. The ratio has changed from one (1) ADS to one (1) ordinary share to the new ratio of one (1) ADS to ten (10) ordinary shares. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release dated January 22, 2024. |
Field: Page; Sequence: 3
Field: /Page
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ​ | Evaxion Biotech A/S | |
|---|---|---|
| ​ | ​ | |
| Date: January 22, | ||
| 2024 | By: | /s/ |
| Christian Kanstrup | ||
| ​ | ​ | Name: Christian Kanstrup |
| ​ | ​ | Title: Chief Executive |
| Officer |
Field: Page; Sequence: 4; Options: Last
Field: /Page